Cytomegalovirus-specific T cells - ViraCyte

Drug Profile

Cytomegalovirus-specific T cells - ViraCyte

Alternative Names: CMV-specific T cell therapy - ViraCyte; CMV-specific T cells - ViraCyte; Cytomegalovirus-specific T cell therapy - ViraCyte; HLA-matched Viralym-C cells; Human leukocyte antigen (HLA)-matched CMV-specific T lymphocytes - ViraCyte; Viralym-C

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViraCyte
  • Class T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 11 Jul 2017 Updated efficacy data from a phase I trial in Cytomegalovirus infections released by ViraCyte
  • 11 Jul 2017 ViraCyte completes a phase I trial in Cytomegalovirus infections (In children, In adolescents, In adults) in USA
  • 24 Jan 2017 Cytomegalovirus-specific T cells - ViraCyte receives Orphan Drug status for Cytomegalovirus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top